Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 15/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711810 | 1.00 | HTT (0.41) | HTTPOLBGRM2GAAALDH1A1 | |
| SCHEMBL1711838 | 1.00 | HTT (0.41) | HTTPOLBGRM2GAAALDH1A1 | |
| SCHEMBL632943 | 0.92 | HTT (0.41) | HTTPOLBGRM2GAAALDH1A1 | |
| SCHEMBL632942 | 0.92 | HTT (0.41) | HTTPOLBGRM2GAAALDH1A1 | |
| SCHEMBL633071 | 0.92 | HTT (0.41) | HTTPOLBGRM2GAAALDH1A1 | |
| SCHEMBL1222807 | 0.90 | HTT (0.43) | HTTPOLBGRM2ALDH1A1LMNA | |
| SCHEMBL1712026 | 0.90 | GRM2 (0.41) | HTTGRM2GAA | |
| SCHEMBL2239583 | 0.90 | HTT (0.43) | HTTPOLBGRM2ALDH1A1LMNA | |
| SCHEMBL1712414 | 0.90 | HTT (0.43) | HTTPOLBGRM2ALDH1A1LMNA | |
| SCHEMBL1712464 | 0.90 | GRM2 (0.41) | HTTGRM2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822114-B2 | Tricyclic oxazolidinone antibiotic compounds | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-11-21 | — | — | US | disclosed |
| EP-2344485-B1 | OXAZOLIDINYL ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-03-22 | — | — | EP | disclosed |
| US-20160237088-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-08-18 | — | — | US | disclosed |
| US-9346804-B2 | Tricyclic oxazolidinone antibiotic compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-05-24 | — | — | US | disclosed |
| EP-2344495-B1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-12-31 | — | — | EP | disclosed |
| US-20140142093-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-05-22 | — | — | US | disclosed |
| US-8618092-B2 | Tricyclic oxazolidinone antibiotic compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-12-31 | — | — | US | disclosed |
| US-8507478-B2 | Oxazolidinyl antibiotics | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-08-13 | — | — | US | disclosed |
| EP-2254887-B9 | OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-05-29 | — | — | EP | disclosed |
| EP-2257551-B1 | AZATRICYCLIC ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-10 | — | — | EP | disclosed |
| US-8349828-B2 | Azatricyclic antibiotic compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-01-08 | — | — | US | disclosed |
| EP-2254887-B1 | OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-12-19 | — | — | EP | disclosed |
| EP-2346862-B1 | 2-BENZOTHIOPHENYL-AND 2-NAPHTHYL-0XAZ0LIDIN0NES AND THEIR AZAISOSTERE ANALOGUES AS ANTIBACTERIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-09-12 | — | — | EP | disclosed |
| US-20110201595-A1 | OXAZOLIDINYL ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-18 | — | — | US | disclosed |
| US-20110195961-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-11 | — | — | US | disclosed |
| US-20110195949-A1 | 2-BENZOTHIOPHENYL- AND 2-NAPHTHYL-OXAZOLIDINONES AND THEIR AZAISOSTERE ANALOGUES AS ANTIBACTERIAL AGENTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-11 | — | — | US | disclosed |
| US-20100331308-A1 | OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-12-30 | — | — | US | disclosed |
| US-20100331318-A1 | AZATRICYCLIC ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-12-30 | — | — | US | disclosed |
| EP-2257551-A2 | AZATRICYCLIC ANTIBIOTIC COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009104147-A2 | AZATRICYCLIC ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201595-A1 | OXAZOLIDINYL ANTIBIOTICS | OXA1L, UBE2D3, PYM1 | HTT 3560/4885POLB 1206/4885GRM2 3020/4885 |
| US-20100331308-A1 | OXAZOLIDINONE DERIVATIVES | OXA1L, UQCRB, O60361 | HTT 4236/4885POLB 40/4885GRM2 2840/4885 |
| US-20100331318-A1 | AZATRICYCLIC ANTIBIOTIC COMPOUNDS | ZYX, AZI2, NAT1 | HTT 2071/4885POLB 2356/4885GRM2 4248/4885 |
| US-20110195949-A1 | 2-BENZOTHIOPHENYL- AND 2-NAPHTHYL-OXAZOLIDINONES AND THEIR AZAISOSTERE ANALOGUES AS ANTIBACTERIAL AGENTS | UQCRB, XDH, TOP2B | HTT 4353/4885POLB 108/4885GRM2 4123/4885 |
| US-20110195961-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | HRH3, OXA1L, HRH1 | HTT 2498/4885POLB 1606/4885GRM2 2558/4885 |
| US-20160237088-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | H1-3, HRH3, HRH4 | HTT 2075/4885POLB 1676/4885GRM2 2253/4885 |
| US-20140142093-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | OXA1L, H1-3, NGLY1 | HTT 2206/4885POLB 1934/4885GRM2 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.